Shares of Bio-Techne Corp. shed 3.71% to $71.83 Wednesday, on what proved to be an all-around dismal trading session for the ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

In a report released today, Tim Anderson from Bank of America Securities reiterated a Sell rating on Amgen (AMGN – Research Report), with a ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amgen Inc (AMGN) stock saw a decline, ending the day at $280.3 which represents a decrease of $-2.65 or -0.94% from the prior close of $282.95. The stock opened at $280.13 and touched a low of $279.97 ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...

As CTO, Mr. Beneski will oversee Allogene's technical operations, leveraging his extensive expertise in biologics ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

The International Society of Pharmaceutical Engineering (ISPE) has announced the 2025 Facility of the Year submission finalists. Each of the submission finalists' projects succeeded in meeting the ...